How COVID-19 vaccine options are expanding with another EUA

The Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to the SARS-CoV-2 vaccine developed by Moderna Inc. for use in people 18 or older. The vaccine joins Pfizer-BioNTech’s vaccine, which earned FDA authorization last week.

Both vaccines use the messenger RNA technology, consist of two separate doses per patient, and have shown about 95% efficacy in protecting against COVID-19, compared with placebo, in clinical trials involving tens of thousands of participants.

Moderna has said it plans to ship 20 million U.S. doses in December, another 80 million by March 2021, and an additional 100 million by June 2021.

My latest for the AMA. The whole shebang.